Aridis Pharmaceuticals, Inc, a United States-based biopharmaceutical company, has reported its financial results for the second quarter of fiscal 2020, it was reported on Tuesday.
The company reported an increase in grant revenue to USD1m for second quarter ended 30 June 2020 from zero for the quarter ended 30 June 2019.
The firm posted net loss for the quarter ended 30 June 2019 at around USD4.2m or USD0.47 loss per share, compared to a net loss of around USD8.4m or USD1.03 net loss per share for the year-ago period.
'The second quarter proved to be a strong period of progress as we continue on our mission to become the leader in developing novel anti-infective treatments for lung infections,' commented Vu Truong, PhD, Aridis Pharmaceuticals' chief executive officer.
DATROWAY receives US priority review for first-line metastatic triple negative breast cancer
Valneva and Instituto Butantan launch pilot chikungunya vaccination campaign in Brazil
Natera submits Signatera CDx PMA to FDA for bladder cancer use
Astrazeneca Imfinzi perioperative regimen gains positive EU CHMP opinion in early gastric cancer
I Peace generates human iPS cells from NKT cells and offers them for research use
Frontage expands early phase clinical research capabilities across US and China
AstraZeneca agrees obesity and type 2 diabetes collaboration with CSPC
Formation Bio acquires worldwide rights to FHND5032 from CTFH
Summit Therapeutics' BLA for ivonescimab in EGFR-mutated NSCLC accepted by FDA
Almirall receives China approval for Seysara to treat moderate-to-severe acne